Novel modes of antifungal drug administration
- 1 August 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 13 (8) , 903-932
- https://doi.org/10.1517/13543784.13.8.903
Abstract
Administration of antifungals by routes other than that for which the agent was designed or approved have been utilised in attempts to provide directed therapy, reduce adverse effects and improve drug penetration into selected infection sites, such as the central nervous system, lungs and peritoneum. The most widely investigated agent utilising a novel method of drug delivery is amphotericin B. Dose forms for this agent include topicals (aerosol, nasal spray, irrigations, pastes, absorbable sponges, impregnated bone cement and gelatin), oral dosage forms (solutions, suspensions, tablets and so on) and ophthalmic preparations (drops, ointments and injections). Amphotericin B has been administered by routes such as oral, endobronchial, intrathecal, intracisternal, intra-articular, intraperitoneal, ophthalmic and as an antibiotic ‘line lock’. Nystatin has been administered as an aerosol, percutaneous paste and bladder washes. Azoles, such as miconazole, fluconazole, ketoconazole and posaconazole, have been administered by novel methods but to a lesser degree. Most of these reports involve miconazole. The dose forms and routes of administration for azoles have included irrigants (bladder, joint), ophthalmic preparations (eye drops, intraocular injections, ointments), impregnated bone cement, endobronchial and intrathecal administration. Finally, both methylene blue (bladder washes) and flucytosine (peritoneal lavage, ophthalmic eye drops) have also been employed. Adequate evaluations of both the safety and efficacy of these therapies are most often hindered by prior or concomitant antifungal therapies, comorbidities and the lack of controlled clinical trials. In addition, the availability of newer treatment options, which demonstrate significant improvement in drug distribution and treatment-related adverse effects make many such novel modes of administration less practical or necessary. In contrast, the inhalation of antifungal aerosols, such as amphotericin B, is rapidly becoming a viable prophylactic option.Keywords
This publication has 149 references indexed in Scilit:
- Aggressive cutaneous aspergillus infection: Control by local irrigation with amphotericin BMedical and Pediatric Oncology, 2002
- Colletotrichum graminicolaCornea, 1997
- Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: A single center experience from 1980 to 1995Infection, 1996
- Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosisInfection, 1996
- Fungal Urinary Tract Infections in the ElderlyDrugs & Aging, 1996
- Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignanciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993
- Amphotericin B in the Treatment of CoccidioidomycosisDrugs, 1983
- Complications with the Ommaya reservoir in patients with granulomatous meningitisJournal of Neurosurgery, 1973
- Neonatal candidiasis, meningitis, andarthritis: Observations and a review of the literatureThe Journal of Pediatrics, 1972
- Local treatment of aspergilloma of the lung with a paste containing nystatin or amphotericin BTubercle, 1970